Exelixis Inc (EXEL) is a biopharmaceutical company that specializes in the development and commercialization of innovative therapies for the treatment of cancer. As an investor, it is essential to analyze the stock from a technical perspective to make informed decisions. Technical indicators provide valuable insights into the stock's price trends and possible future movements.

One of the key technical indicators to consider is the Relative Strength Index (RSI), which measures the speed and change of price movements. It ranges from 0 to 100, with values above 70 indicating overbought conditions and values below 30 indicating oversold conditions. By analyzing EXEL's RSI, investors can gain insights into whether the stock is overbought or oversold and make appropriate investment decisions.

Exelixis  (EXEL) Technical Analysis

Learn about Exelixis Inc (EXEL) technical analysis indicators including RSI, ADX, MACD, ROC, STOCHRSI, and WILLR. Get insights into the stock's performance and ratings in this comprehensive analysis.

Exelixis Inc (EXEL) Technical Analysis: Indicators, RSI, ADX, MACD, ROC, STOCHRSI, WILLR Ratings

Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human monoclonal antibody against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Exelixis 

NASDAQ

This suggests that the technical indicators do not strongly favor either a buying or selling stance. In such cases, investors may need to rely on additional fundamental or market analysis to make a well-informed decision.

Balanced or Uncertain

MACD

WILLR

STOCHRSI

Free

is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.

Name	Value	Action	infoPnL (10y)
auto_graphRSI	47.64	Neutral	18.1%
auto_graphMACD	0.24	Neutral	-59.4%
auto_graphCCI	-71.18	Neutral	166.7%
auto_graphADX	38.13	Neutral	-61.8%
auto_graphATR	1.60	Buy	-
auto_graphWILLR	-87.57	Buy	118.6%
auto_graphROC	-23.81	Neutral	-60.6%
auto_graphSTOCHRSI	20.70	Neutral	59.8%

Buy	2	-75.00%
Hold	6	-25.00%
Sell	0	-100.00%

Trendlines, Support and Resistance

Welcome to Stocklytics

Technical Indicators

Indicator Ratings

Balanced or Uncertain

Exelixis (EXEL) Technical Analysis

Keep an eye on Exelixis

Frequently Asked Questions

What are the technical signals for Exelixis (EXEL) stock based on the last 30 days?

Take Your Investments to a Whole New Level